Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 700.00% | -88.06% | -- | -100.00% | -98.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 700.00% | -88.06% | -- | -100.00% | -98.48% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 700.00% | -88.06% | -- | -100.00% | -98.48% |
| SG&A Expenses | 43.16% | 38.90% | 30.41% | 21.45% | 23.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.05% | 31.33% | 30.01% | 30.34% | 26.14% |
| Operating Income | -15.72% | -367.04% | -348.15% | -309.41% | -298.90% |
| Income Before Tax | -10.09% | -330.73% | -345.53% | -323.02% | -313.03% |
| Income Tax Expenses | -- | -- | -- | -119.00% | -132.10% |
| Earnings from Continuing Operations | -10.59% | -335.93% | -351.04% | -328.36% | -318.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.59% | -335.93% | -351.04% | -328.36% | -318.68% |
| EBIT | -15.72% | -367.04% | -348.15% | -309.41% | -298.90% |
| EBITDA | -16.83% | -347.77% | -330.76% | -294.54% | -283.46% |
| EPS Basic | 82.28% | -241.08% | -318.12% | 42.56% | -67.81% |
| Normalized Basic EPS | 88.97% | -106.90% | -112.46% | -151.33% | -187.04% |
| EPS Diluted | 82.61% | 63.67% | 55.82% | 70.34% | 14.48% |
| Normalized Diluted EPS | 88.97% | -173.01% | 55.71% | -157.86% | -228.47% |
| Average Basic Shares Outstanding | 174.44% | 448.75% | 1,690.48% | 1,174.32% | 725.32% |
| Average Diluted Shares Outstanding | 174.44% | 404.85% | 1,250.76% | 858.45% | 519.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |